跳转至内容
Merck
CN

S8251

Sigma-Aldrich

氯化琥珀胆碱二水合物 二水合物

98.0-102.0%, Cholinergic antagonist, solid

别名:

琥珀酰氯化胆碱

登录查看公司和协议定价

关于此项目

线性分子式:
[(CH3)3NCH2CH2OCOCH2]2Cl2 · 2H2O
CAS Number:
分子量:
397.34
Beilstein:
3922827
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.77
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Product Name

氯化琥珀胆碱二水合物 二水合物, 98.0-102.0%, solid

质量水平

方案

98.0-102.0%

表单

solid

颜色

white

溶解性

H2O: complete 100 mg/ml, clear to slightly hazy, colorless
H2O: soluble (unstable at pH > 9.)

创始人

Novartis

SMILES字符串

O.O.[Cl-].[Cl-].C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C

InChI

1S/C14H30N2O4.2ClH.2H2O/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6;;;;/h7-12H2,1-6H3;2*1H;2*1H2/q+2;;;;/p-2

InChI key

FFSBEIRFVXGRPR-UHFFFAOYSA-L

正在寻找类似产品? 访问 产品对比指南

应用

氯化琥珀胆碱用于研究非洲爪蟾 半胱氨酸环受体的门控机制。4,5

生化/生理作用

琥珀胆碱是胆碱能拮抗剂和神经肌肉阻断剂。它诱导肌肉膜上乙酰胆碱受体的去极化和肌肉中钾的流出,导致乙酰胆碱受体表达上调的个体发生低钾血症。3
胆碱能拮抗剂,可诱导乙酰胆碱神经元膜的长期去极化;神经肌肉阻断剂。

特点和优势

该化合物由 Novartis 开发。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单,请单击此处

制备说明

溶液可以在 4℃ 下储存数天。

象形图

Skull and crossbones

警示用语:

Danger

危险声明

预防措施声明

危险分类

Acute Tox. 3 Oral

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)

法规信息

危险化学品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Brandon H Cline et al.
BMC neuroscience, 13, 110-110 (2012-09-20)
A number of epidemiological studies have established a link between insulin resistance and the prevalence of depression. The occurrence of depression was found to precede the onset of diabetes and was hypothesized to be associated with inherited inter-related insufficiency of
Xinan Xiu et al.
The Journal of biological chemistry, 280(50), 41655-41666 (2005-10-12)
In the Cys loop superfamily of ligand-gated ion channels, a global conformational change, initiated by agonist binding, results in channel opening and the passage of ions across the cell membrane. The detailed mechanism of channel gating is a subject that
Franklin Dexter et al.
Anesthesia and analgesia, 116(1), 118-122 (2012-12-12)
Facilities with volatile anesthetic agents stock dantrolene for the treatment of malignant hyperthermia (MH). The availability of dantrolene at these facilities satisfies cost-utility norms even for sites with as few as 1 anesthetic per workday, based on the overall incidence
Claus Bretlau et al.
Anesthesia and analgesia, 116(3), 596-601 (2013-02-13)
Succinylcholine is usually metabolized quickly by the butyrylcholinesterase enzyme (BChE) but genetic variants of BChE may prolong the duration of action. The Kalow (K) variant is the most common mutation in the butyrylcholinesterase gene (BCHE), being present in 25% of
Leal G Segura et al.
Paediatric anaesthesia, 23(9), 855-864 (2013-08-08)
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are associated with life-threatening perioperative complications, including rhabdomyolysis, hyperkalemia, and hyperthermia. Current recommendations contraindicate use of succinylcholine and volatile anesthetics; however, the latter recommendation remains controversial. To review the perioperative outcomes

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持